Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment

Hillstar Bio以6700万美元的A轮融资启动，致力于开发下一代精准免疫疗法，变革自身免疫治疗。

Proceeds to fund advancement of the company's lead TRBV9 program through clinical proof-of-concept study in axial spondyloarthritis and progression of broader pipeline

收益将用于推动公司主导的TRBV9项目在轴向脊柱关节炎领域的临床概念验证研究，以及更广泛的研发管线的进展。

Company's approach selectively targets and depletes pathogenic immune cells with the potential to reset the immune system, offering more durable therapeutic responses

公司的方法有针对性地清除致病性免疫细胞，有可能重置免疫系统，提供更持久的治疗效果。

BOSTON, March 25, 2025-- Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the successful closing of a $67 million Series A financing round. This funding was led by a syndicate of experienced investors and shareholders from the U.S., Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures, and Hummingbird Bioscience..

波士顿，2025年3月25日——Hillstar Bio是一家领先的生物技术公司，专注于为自身免疫疾病开发下一代精准免疫疗法。该公司今天宣布成功完成了6700万美元的A轮融资。本轮融资由来自美国、欧洲和亚洲的经验丰富的投资者和股东组成的财团领投，其中包括Droia Ventures、Frazier Life Sciences、Novo Holdings A/S、LifeArc Ventures和Hummingbird Bioscience。

Hillstar Bio is revolutionizing autoimmune disease treatment through a precision-driven approach that selectively depletes pathogenic cells while preserving healthy ones. This method holds the promise of providing durable relief and improving patient outcomes compared to traditional immunosuppressive therapies.

Hillstar Bio 正在通过一种精准驱动的方法彻底改变自身免疫性疾病的治疗，该方法能够选择性地清除致病细胞，同时保留健康细胞。与传统的免疫抑制疗法相比，这种方法有望提供持久的缓解并改善患者的治疗效果。

Additionally, the company's versatile approach leverages tailored discovery techniques for each therapeutic, free from the constraints of traditional drug development platforms..

此外，该公司采用多功能的方法，为每种疗法量身定制发现技术，不受传统药物开发平台的限制。

The new funding will propel Hillstar Bio's lead program, which specifically targets TRBV9+ T cells, into clinical trials in 2026. Initially, the focus will be on treating axial spondyloarthritis (AxSpA) and potentially other immune and inflammatory conditions associated with HLA-B27. The investment will also support the expansion of Hillstar Bio's portfolio, which includes a variety of precision immunology therapies aimed at specific immune cell subsets across a range of autoimmune diseases..

新资金将推动Hillstar Bio的核心项目于2026年进入临床试验，该项目专门针对TRBV9+ T细胞。最初，研究重点将是治疗轴性脊柱关节炎（AxSpA），并可能扩展到与HLA-B27相关的其他免疫和炎症疾病。这笔投资还将支持Hillstar Bio产品组合的扩展，其中包括多种精准免疫学疗法，旨在针对多种自身免疫疾病中的特定免疫细胞亚群。

'The interplay between HLA-B27 and TRBV9+ T cells in autoimmune conditions like AxSpA offers a unique opportunity for our lead program,' said Robert Mabry, CEO of Hillstar Bio. 'Our innovative approach aims to deliver longer-lasting, more effective results compared to current treatments, improving patient outcomes and potentially reducing the long-term need for immunosuppressive therapies.'.

“HLA-B27与TRBV9+ T细胞在AxSpA等自身免疫疾病中的相互作用为我们的主导项目提供了独特的机会，”Hillstar Bio首席执行官罗伯特·梅布里表示。“我们的创新方法旨在提供比现有治疗更持久、更有效的结果，改善患者预后，并可能减少对长期免疫抑制疗法的需求。”

Hillstar Bio boasts a world-class team with deep expertise in antibody engineering, immunology, and clinical development. The company's approach combines cutting-edge scientific knowledge with a robust, risk-mitigating strategy, leveraging validated technologies and disease-specific biomarkers to identify the patient populations most likely to benefit from their treatments..

希尔施塔生物公司拥有一个世界级的团队，在抗体工程、免疫学和临床开发方面具有深厚的专业知识。该公司的方法结合了前沿的科学知识和强有力的风险缓解策略，利用经过验证的技术和疾病特异性生物标志物来确定最有可能从其治疗中受益的患者群体。

'We are excited to collaborate with the Hillstar Bio team in bringing groundbreaking, precision-driven immunotherapies to patients living with autoimmune diseases,' said Luc Dochez, Executive Chair at Hillstar Bio and Managing Partner at Droia Ventures. 'Hillstar Bio has the critical elements necessary to transform autoimmune disease treatment, including top-tier antibody engineering capabilities, a deep understanding of immune cell biology, and an exceptional team of scientists, industry leaders, and advisors.'.

“我们很高兴与Hillstar Bio团队合作，为患有自身免疫性疾病的患者带来突破性的、精准驱动的免疫疗法，”Hillstar Bio执行主席兼Droia Ventures管理合伙人Luc Dochez表示。“Hillstar Bio具备改变自身免疫疾病治疗的关键要素，包括顶级的抗体工程能力、对免疫细胞生物学的深刻理解，以及一支由科学家、行业领袖和顾问组成的卓越团队。”

The company's leadership include:

公司领导层包括：

Hillstar Bio Executive Team

希尔斯特生物执行团队

• Robert Mabry, Ph.D., Chief Executive Officer, previously Chief Scientific Officer at Orna Therapeutics and Global Head of Biologics at Takeda

• 罗伯特·马布里，博士，首席执行官，曾担任Orna Therapeutics的首席科学官和武田制药的全球生物制品主管

• Mitchell Keegan, Ph.D., Chief Development Officer, previously SVP of Clinical Development at Boston Pharmaceuticals and VP of Clinical Development at Verastem Oncology

• Mitchell Keegan，博士，首席开发官，曾担任Boston Pharmaceuticals临床开发高级副总裁和Verastem Oncology临床开发副总裁

• Lauren Mifflin, Ph.D., MBA, Chief Operating Officer, Principal of Company Creation at Frazier Life Sciences, previously on the founding teams of multiple venture-backed biotechs, including Ypsilon Therapeutics, Nido Biosciences, and Entrada Therapeutics.

• Lauren Mifflin，博士，MBA，Frazier生命科学公司首席运营官兼公司创建负责人，曾参与多个风险投资支持的生物技术公司的创始团队，包括Ypsilon治疗公司、Nido生物科学公司和Entrada治疗公司。

Board of Directors

董事会

• Luc Dochez, Pharm.D., MBA, Executive Chair, Managing Partner, Droia Ventures

• Luc Dochez，药学博士，工商管理硕士，执行主席，管理合伙人，Droia Ventures

• Dan Estes, Ph.D., General Partner, Frazier Life Sciences

• 丹·埃斯蒂斯，博士，普通合伙人，弗雷泽生命科学

• Kenneth Harrison, Ph.D., Senior Partner, Novo Holdings A/S

肯尼斯·哈里森博士，高级合伙人，诺和控股有限公司

• Piers Ingram, Ph.D., MBA, Chief Executive Officer, Hummingbird Bioscience

• 皮尔斯·英格拉姆，博士，工商管理硕士，首席执行官，蜂鸟生物科学

• Robert Mabry, Ph.D., Chief Executive Officer, Hillstar Bio

• 罗伯特·马布里，博士，首席执行官，希尔斯特生物

• Matthias Van Woensel, Ph.D., Partner, Droia Ventures

• 马蒂亚斯·范·沃森尔，博士，合伙人，Droia Ventures

About Hillstar Bio

关于希尔施塔生物

Hillstar Bio is ushering in a new era in autoimmune disease treatment through precision immunology. The company selectively targets and depletes pathogenic immune cells while sparing healthy ones, offering the potential for durable relief and immune reset for patients with autoimmune conditions. Unlike traditional therapies that broadly suppress the immune system, Hillstar Bio's targeted approach addresses specific disease mechanisms by eliminating the underlying source and reducing the risks associated with chronic broad immunosuppression.

Hillstar Bio正通过精准免疫学开创自身免疫疾病治疗的新时代。该公司选择性地靶向并清除致病的免疫细胞，同时保留健康细胞，为自身免疫疾病患者提供持久缓解和免疫系统重置的潜力。与广泛抑制免疫系统的传统疗法不同，Hillstar Bio的靶向方法通过消除根本病因来应对特定疾病机制，降低了长期广泛免疫抑制带来的风险。

Backed by an experienced investor and shareholder syndicate spanning the US, Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures and Hummingbird Bioscience, Hillstar Bio is fully funded through early clinical studies to accelerate development of its TRBV9 program while expanding its pipeline of selective immune cell targeting therapies.

凭借来自美国、欧洲和亚洲的资深投资者和股东财团的大力支持，包括Droia Ventures、Frazier Life Sciences、Novo Holdings A/S、LifeArc Ventures以及Hummingbird Bioscience，Hillstar Bio已获得充足的资金支持，以推动其TRBV9项目早期临床研究的加速开发，同时扩展其选择性免疫细胞靶向治疗的研发管线。

To learn more visit www.hillstarbio.com and follow the company on LinkedIn..

要了解更多信息，请访问 www.hillstarbio.com 并在 LinkedIn 上关注该公司。

Contact:

联系：

Media Contact:

媒体联系人：

Media@Hillstarbio.com

媒体@希尔之星生物.com